MaRS Monthly Roundup — September 2024

Published on September 5, 2024

A summer of success! Check out a month’s worth of venture accomplishments in our MaRS monthly roundup.

The post MaRS Monthly Roundup — September 2024 appeared first on MaRS Discovery District.

Continue reading on website
Other news

Abdera Therapeutics Announces FDA Orphan Drug Designation for ABD-147 for the Treatment of Neuroendocrine Carcinoma

September 5, 2024
SOUTH SAN FRANCISCO, CA, September 5, 2024 – Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ABD-147 for the treatment of neuroendocrine carcinoma. ABD-147

Astellas unveils Massachusetts lab that will be shared with biotechs, academia researchers

September 6, 2024
Astellas Pharma has cut the ribbon on a new life sciences center in Massachusetts that will house 400 team members and an incubator lab.The Astellas Life Sciences Center includes the drugmaker’s first U.S.-based SakuLab that will be shared with external partners. The labs are inspired by the Japanese word "saku," which means "to bloom," and are designed to be a place where bold and diverse ideas c